ReviewCurrent microbiology2021
Current Understanding of the Pathogenesis of Dengue Virus Infection.
Review in Current microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 174 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
174 citing papers in PubMed, 2 syntheses or guidelines pooled it, 344 citations in OpenAlex.
- Deep Generative Models for the Discovery of Antiviral Peptides Targeting Dengue Virus: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Increasing prevalence of malaria and acute dengue virus coinfection in Africa: a meta-analysis and meta-regression of cross-sectional studies.Malaria journal · 2023Pooled it
- Antibodies Produced in Response to a Live-Attenuated Dengue Vaccine Are Functional in Activating the Complement System.The Journal of infectious diseases · 2023Trial
- Small extracellular vesicles from DENV2-infected C6/36 cells show viral infectionEmerging microbes & infections · 2026Article
- Impact of delayed medical consultation on dengue severity and mortality during the 2023 outbreak in Burkina Faso.IJID regions · 2026Article
- Antibody-Dependent Enhancement in Flavivirus Infections: From Fc Receptor Signaling to Vaccine and Therapeutic Design.Viruses · 2026Review
- Computational approaches for flavivirus drug discovery: targeting structural and non-structural proteins.RSC medicinal chemistry · 2026Review
- Serological and Immunological Markers in Dengue Fever: A Retrospective ELISA-Based Pilot Study from Trinidad and Tobago.Diagnostics (Basel, Switzerland) · 2026Article
- Nanoparticle vaccine formulations for dengue virus.RSC pharmaceutics · 2026Review
- Causes of Fever in a Cohort of Nepali Children and the Potential Impact of Molecular Testing During a Dengue Fever Outbreak.The Pediatric infectious disease journal · 2026Article
- Beyond Hemostasis: Platelet Biomarkers and Vascular-Immune Crosstalk in Dengue.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Review
- Unveiling the molecular mechanism of Qingwen Baidu decoction against dengue fever: an integrated study of bioinformatic analysis, machine learning and network pharmacology.Functional & integrative genomics · 2026Article
- Decoding Thrombocytopenia in Dengue: Platelet Indices Define Mechanistic Phenotypes and Predict Bleeding Risk.Cureus · 2026Article
- Exploring anti-dengue activity with atomic-weighted vectors, class balancing and machine learning.Molecular diversity · 2026Article
- Metabolomic atlas of dengue virus infection reveals distinct circulating bioactive lipid signatures.PLoS neglected tropical diseases · 2026Article
- DENcode: A model for haplotype-informed transmission probability of dengue virus.PLoS computational biology · 2026Article
- Strain-specific pathogenicity and antibody-dependent enhancement of dengue virus infection inThe Journal of general virology · 2026Article
- Purinergic signaling in dengue infection: modulation of P2 receptors as a potential therapeutic strategy.Purinergic signalling · 2026Review
- Article
- Epidemiological Characteristics of Dengue Disease in Mexico (2014-2025): A Descriptive Analysis of a Hyperendemic Country.Pathogens (Basel, Switzerland) · 2026Review
114 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The pathogenesis of dengue virus infection is attributed to complex interplay between virus, host genes and host immune response. Host factors such as antibody-dependent enhancement (ADE), memory cross-reactive T cells, anti-DENV NS1 antibodies, autoimmunity as well as genetic factors are major determinants of disease susceptibility. NS1 protein and anti-DENV NS1 antibodies were believed to be responsible for pathogenesis of severe dengue. The cytokine response of cross-reactive CD4+ T cells might be altered by the sequential infection with different DENV serotypes, leading to further elevation of pro-inflammatory cytokines contributing a detrimental immune response. Fcγ receptor-mediated antibody-dependent enhancement (ADE) results in release of cytokines from immune cells leading to vascular endothelial cell dysfunction and increased vascular permeability. Genomic variation of dengue virus and subgenomic flavivirus RNA (sfRNA) suppressing host immune response are viral determinants of disease severity. Dengue infection can lead to the generation of autoantibodies against DENV NS1antigen, DENV prM, and E proteins, which can cross-react with several self-antigens such as plasminogen, integrin, and platelet cells. Apart from viral factors, several host genetic factors and gene polymorphisms also have a role to play in pathogenesis of DENV infection. This review article highlights the various factors responsible for the pathogenesis of dengue and also highlights the recent advances in the field related to biomarkers which can be used in future for predicting severe disease outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.